Jean Donadieu

MD Ph D

Assistance Publique - Hôpitaux de Paris
Country flagFrance

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (13)

We evaluated long-term outcomes of 288 children with refractory-Langerhans cell histiocytosis (R-LCH) from 26 countries prescribed off-label mitogen-activated protein kinase inhibitors (MAPKis) according to clinical indications. MAPKi indications were: 148 R-risk-organ-positive (R-RO+), 67 R-RO-negative (R-RO-), 13 lung destruction (lung), 9 sclerosing cholangitis (SC), 49 neurodegeneration (ND) and 2 diabetes insipidus (DI). Median ages at diagnosis and MAPKi onset were 1.3 and 2.3 years, respectively, with median follow-up of 3.7 years (1166 person-years). Agents were mostly prescribed as monotherapies: 184 vemurafenib, 115 dabrafenib, 3 encorafenib, 42 cobimetinib, 45 trametinib and/or 1 binimetinib; followed 51 times by various chemotherapies or hematopoietic stem-cell transplantation, or combined anti-BRAF-anti-MEK 28 times. Short-term responses (<8 weeks) ranged from 98% (R-RO+ and R-RO-), to 30% (lung) to none (ND, DI and SC), although long-term lung and ND responses could be observed. Skin rash was the most frequent adverse event (~55%); 7 others were 1 cardiomyopathy and 6 retinitis. Five developed MAPKi-unrelated tumors. Nine patients died. Five-year survival was 98%. After 113 patients with R-LCH discontinued MAPKi, 69 experienced disease reactivation. None of the various empirical maintenance therapies were able to prevent secondary reactivation. Among the 143 assessable patients without ND-LCH at MAPKi onset, 60 developed ND: 45% 5-year risk. MAPKis appeared to be safe and effective in children with R-RO+/RO-LCH, while other indications' responses were less frequent or occurred later. Further studies are needed to find effective maintenance-therapy approaches, particularly to prevent frequently observed secondary ND.

Year:

2026

Year:

2026

Year:

2026

Year:

2025

Most histiocytoses harbor an oncogenic somatic alteration activating the MAP kinase pathway, the most frequent of which is BRAF V600E . Targeted therapy with BRAF or MEK inhibitors is highly effective, but neurodegeneration remains a severe complication. Recent data suggest that neurodegeneration may be secondary to mosaicism for BRAF V600E in microglia. In the prospective observational TARGET-HISTIO cohort study, we investigated extra-CNS mosaicism of BRAF V600E in a cohort of 124 adults with histiocytosis. Seeking widespread mosaicism, we analyzed healthy skin biopsies from areas without histiocytosis or melanocytic infiltration using high-sensitivity digital polymerase chain reaction. BRAF V600E was detected in healthy skin in 57/67 (85%) patients with BRAF V600E histiocytosis and was present in all second and third skin biopsies (n=6). BRAF V600E was absent from skin biopsies in all 37 patients with histiocytosis harboring another oncogenic mutation. BRAF V600E was also present in skin biopsies of four /20 patients with histiocytosis of unknown molecular status. Cells harboring BRAF V600E share characteristics with resident dermis macrophages. Only 58% of patients with BRAF V600E in skin also had BRAF V600E in blood leukocytes. Variant allele frequency in skin and blood leukocytes was 16 times lower than in histiocytosis, and frequency in skin was independent of treatment with BRAF/MEK inhibitors. None of the patients with wild type BRAF alleles in skin had neurodegeneration, whereas 22/61 (36%) of patients with BRAF V600E in skin had neurodegeneration. This study demonstrates that mosaicism of BRAF V600E in healthy skin is frequent in patients with histiocytosis and is strongly associated with neurodegeneration. Key Points Low allele frequency of the oncogene BRAF V600E is frequent in healthy skin of patients with histiocytosis. Patients without BRAF V600E in skin do not develop neurodegeneration, while 36% of those with BRAF V600E mosaicism do.

Year:

2025

Congenital neutropenia (CN) comprises a heterogeneous group of rare genetic disorders. While some CN cases present only with neutropenia, others present with additional extra‐hematological manifestations. The most common cause of CN is variants in ELANE ; however, approximately 30 other genes have been implicated. Despite this, the genetic basis remains unknown in roughly 30% of cases. The clinical and genetic heterogeneity of CN makes diagnosis particularly challenging. To address this, we conducted exome or genome sequencing of 60 patients with a suspected diagnosis of CN that remained unresolved following targeted sequencing. A genetic diagnosis was established in 25 patients (42%). Variants were identified in 15 different genes. Half of these cases involved genes traditionally associated with hereditary immunodeficiencies ( GINS4 , CARD11 , ADA2 , GINS1 , LCP1 , SASH3 , and WAS ). One‐third of the cases carried variants in genes linked to syndromic disorders ( VPS13B , TAFAZZIN , CLPB , and TONSL ), demonstrating variable penetrance of extra‐hematological phenotypes. A smaller subset (15%) harbored variants in genes associated with inherited bone marrow failure syndromes ( BLM , RPL18 , SAMD9 , and SRP72 ), identified incidentally due to atypical presentations. Compared to patients with ELANE‐CN, these individuals were diagnosed later, had fewer severe bacterial infections and gingivitis, exhibited less profound neutropenia, lacked monocytosis, and had a granulocytic maturation arrest, often beyond the promyelocytic stage. A shared feature among these cases was a tendency toward reduced lymphocyte subsets, particularly NK cells. This study highlights the significant contribution of exome and genome sequencing in diagnosing CN, given the phenotypic overlap, genetic heterogeneity, and variable penetrance of immunological and extra‐hematological features.

Year:

2025

Non-Langerhans cell histiocytoses are a diverse group of histiocytic diseases. Different entities are defined based on clinical, histopathologic, and/or molecular characteristics. This study aimed to define NTRK-rearranged histiocytosis. Through international collaboration, we investigated 50 cases of histiocytosis with pan-tropomyosin receptor kinase (pan-TRK) expression and/or in-frame NTRK rearrangement. We also analyzed 45 control xanthogranulomas using pan-TRK immunohistochemistry and targeted RNA sequencing. Slides were centrally reviewed; clinical and molecular data were collected. The 50 cases comprised 30 children and 20 adults with a median age of 11.5 years (range, 0-73 years) and a male predominance (64%). Most patients (88%) had disease limited to the skin, including a single skin nodule in 41 patients and multiple skin lesions in 3 others. Four newborns presented with skin lesions, hepatomegaly, and thrombocytopenia that required transfusions. The 2 remaining patients had life-threatening lesions of the brain or bronchus. All cases displayed xanthogranuloma histology, often including foamy histiocytes and Touton giant cells. Histiocytes stained positive for pan-TRK in 50 of 50 cases, whereas all 45 control xanthogranulomas without in-frame NTRK fusions stained negative. NTRK1 fusion partners included IRF2BP2 (23/46), TPM3 (12/46), SQSTM1 (3/46), PRDX1 (3/46), NPM1 (2/46), LMNA (2/46), and ARHGEF2 (1/46). Clinical outcomes were favorable, including spontaneous disease regression in 3 of 4 newborns with systemic disease, and rapid clinical response in both patients with a brain or bronchial tumor treated with the TRK inhibitor larotrectinib. This study advances the molecular characterization of histiocytoses and may guide the diagnosis and personalized treatment of patients.

Year:

2025

Year:

2024

Year:

2024

Indeterminate dendritic cell histiocytosis (IDCH) is a rare and poorly understood entity characterized by accumulation of CD1a+/S100+ histiocytes (as Langerhans cell histiocytosis [LCH]) but with reduced-absent expression of Langerin/CD207. We assembled 43 cases of IDCH (defined by CD1a+/CD207<20% immunophenotypic profile) examining the clinical, pathologic, and molecular landscape. Median age at presentation was 70 years (interquartile range, 44-80) with cutaneous (31/43; 72%) and nodal (11/43; 26%) involvement predominating. Eighteen (42%) individuals had an associated nonhistiocytic hematopoietic neoplasm (“secondary” IDCH) whereas 7 of 43 (16%) had a concurrent non-IDCH histiocytosis (“mixed” histiocytosis). Most cases exhibited morphology indistinguishable from LCH but with a CD1c+/CSF1R(CD115)− phenotype, mirroring the signature of normal indeterminate cells and conventional DC type 2. Mutational analysis revealed frequent KRAS (13/32; 41%) and BRAF p.V600E (11/36, 31%) mutations that were nearly mutually exclusive. RNA-sequencing analysis uncovered ETV3::NCOA2 fusion in 6 other patients presenting as a sole genetic alteration without any other concurrent histiocytic or hematopoietic neoplasm. BRAF and MAP2K1 alterations were significantly associated with partial/retained (1%-20%) Langerin expression (P = .005) and mixed histiocytosis (P = .002). Remarkably, myeloid alterations (DNMT3A, TET2, and SRSF2) co-occurred in IDCH tissues of several individuals. Paired sequencing of IDCH and concurrent non-IDCH hematopoietic neoplasm in 4 individuals revealed shared mutations. Age at diagnosis and any nodal involvement at diagnosis predicted inferior overall survival, but BRAF/RAS pathway alterations did not affect outcome. These data have implications for the diagnostic evaluation, classification, and therapeutic management of IDCH.

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Collaborators (18)

Itziar Astigarraga

Profesora Asociada

Universidad del País Vasco Facultad de Farmacia

SPAIN
View details

Christine Bellanné-Chantelot

Head of Molecular Genetics Laboratory

Assistance Publique - Hôpitaux de Paris

FRANCE
View details

Jan-Inge Henter

Karolinska Institutet

SWEDEN
View details

Elaine Jaffe

Head, Hematopathology Section

National Cancer Institute

UNITED STATES
View details

maxime battistella

Assistant professor

Université Paris Diderot

FRANCE
View details

Benjamin Durham

Assistant Professor, Tenure-Track

Rutgers Cancer Institute of New Jersey

UNITED STATES
View details

Elena Sieni

AOU Meyer

ITALY
View details

Astrid G. S. van Halteren

Leiden University Medical Center

NETHERLANDS
View details

Jean-François Emile

Université de Versailles Saint-Quentin-en-Yvelines

FRANCE
View details

Ashish Kumar

Professor

Cincinnati Children's Hospital Medical Center

UNITED STATES
View details

Arndt Borkhardt

Prof

Heinrich Heine University Düsseldorf

GERMANY
View details

Lenka Krsková

First Faculty of Medicine Charles University and University Hospital Motol

CZECH REPUBLIC
View details

Liqiang Xi

Staff Scientist

National Institutes of Health

UNITED STATES
View details

Christine Iacobuzio-Donahue

Memorial Sloan Kettering Cancer Center

UNITED STATES
View details

Svetlana Pack

Staff Scientist

National Institutes of Health

UNITED STATES
View details

Jennifer Picarsic

Professor

University of Pittsburgh

UNITED STATES
View details

Milen Minkov

Full Professor of Specialized Pediatrics

Sigmund Freud PrivatUniversität Wien

AUSTRIA
View details

Francesco Pegoraro

Pediatric Hematologist Oncologist

Università degli Studi di Napoli Federico II

ITALY
View details